Is iShares MSCI Pacific ex Japan ETF (EPP) a Buy, Sell, or Hold?
AMEX : EPP
iShares MSCI Pacific ex Japan ETF — News
$55.15 USD
$0.31 (0.57%)
- Volume
- 150.58K
- Average Volume
- 359.05K
- Market Capitalization
- $2.03B
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $57.07
- Year Low
- $48.93
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
| Source | Headline |
|---|---|
|
SCENESSE® approved for EPP in Canada
Health Canada NOC enables treatment for porphyria, metabolic disorder Health Canada NOC enables treatment for porphyria, metabolic disorder globenewswire.com - 2026-07-13 01:10:00 |
|
GondolaBio Announces Positive Phase 2a Results Demonstrating 79% Plasma Protoporphyrin IX Reduction and Disease-Modifying Potential of PORT-77 for Erythropoietic Protoporphyria
PALO ALTO, Calif.--(BUSINESS WIRE)--GondolaBio, a clinical-stage biopharmaceutical company developing novel medicines for patients living with genetic diseases, on behalf of its affiliate Portal Therapeutics, today announced positive data from its Phase 2a GATEWAY trial of PORT-77 in patients with erythropoietic protoporphyria (EPP). PORT-77 is a novel investigational oral, small molecule ABCG2 inhibitor designed to treat EPP and X-linked protoporphyria (XLP), two rare genetic disorders charact. businesswire.com - 2026-06-22 07:30:00 |
|
Why Japan's $70 billion-plus intervention and a rate hike didn't prop up the yen more
Japan spent about $73 billion on foreign exchange intervention and the Bank of Japan has raised rates, but the yen remains near 160 against the dollar. A wide U.S.-Japan rate gap, carry trades and Prime Minister Sanae Takaichi's reflationary stance continue to weigh on the currency. cnbc.com - 2026-06-18 22:04:53 |
|
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
WATERTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the launch of an expanded access program (EAP) for bitopertin for eligible patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) in the U.S. globenewswire.com - 2026-06-01 08:30:00 |
|
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges
Disc Medicine NASDAQ: IRON Chief Executive Officer John Quisel said patient demand for the company's bitopertin program in erythropoietic protoporphyria, or EPP, remains strong after the company enrolled 183 patients in the APOLLO confirmatory study, above its original target of 150. marketbeat.com - 2026-05-26 00:06:21 |
|
Goldman Sachs says AI and energy resilience are creating a North-South divide in Asian markets
Investors are focusing on AI developments in North Asia. China is coming out of more than three years of deflation measured by the producer price index. cnbc.com - 2026-05-19 20:46:06 |
